D.A. Davidson & CO. Buys 3,088 Shares of Becton, Dickinson and Company $BDX

D.A. Davidson & CO. lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 53,054 shares of the medical instruments supplier’s stock after purchasing an additional 3,088 shares during the period. D.A. Davidson & CO.’s holdings in Becton, Dickinson and Company were worth $9,139,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Becton, Dickinson and Company by 1.5% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 7,653 shares of the medical instruments supplier’s stock worth $1,318,000 after purchasing an additional 116 shares in the last quarter. VCI Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 16.8% during the 2nd quarter. VCI Wealth Management LLC now owns 6,159 shares of the medical instruments supplier’s stock worth $1,061,000 after purchasing an additional 886 shares in the last quarter. Phoenix Financial Ltd. increased its holdings in shares of Becton, Dickinson and Company by 26.8% during the 2nd quarter. Phoenix Financial Ltd. now owns 1,445 shares of the medical instruments supplier’s stock worth $249,000 after acquiring an additional 305 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Becton, Dickinson and Company by 42.3% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 460,083 shares of the medical instruments supplier’s stock worth $79,825,000 after acquiring an additional 136,863 shares during the last quarter. Finally, Canvas Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $470,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Piper Sandler reissued a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Finally, Argus boosted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $205.40.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 1,838 shares of company stock valued at $348,392. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $188.03 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock’s fifty day moving average price is $190.30 and its two-hundred day moving average price is $184.31. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The firm has a market cap of $53.90 billion, a price-to-earnings ratio of 33.82, a P/E/G ratio of 1.48 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion for the quarter. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.